HRP20140488T1 - Cjepivo protiv influence - Google Patents
Cjepivo protiv influence Download PDFInfo
- Publication number
- HRP20140488T1 HRP20140488T1 HRP20140488TT HRP20140488T HRP20140488T1 HR P20140488 T1 HRP20140488 T1 HR P20140488T1 HR P20140488T T HRP20140488T T HR P20140488TT HR P20140488 T HRP20140488 T HR P20140488T HR P20140488 T1 HRP20140488 T1 HR P20140488T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- influenza virus
- adjuvant
- immunogenic
- immunogenic preparation
- Prior art date
Links
- 229960003971 influenza vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 claims 7
- 241000712461 unidentified influenza virus Species 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 5
- 230000000890 antigenic effect Effects 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 238000002255 vaccination Methods 0.000 claims 3
- 239000007764 o/w emulsion Substances 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 238000012770 revaccination Methods 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (3)
1. Drugi imunogeni pripravak koji sadrži virus influence, ili njegov antigenski preparat, namijenjen upotrebi u ponovnom cijepljenju ljudi prethodno cijepljenih prvim imunogenim pripravkom, naznačen time što
– prvi imunogeni pripravak je monovalentni pripravak, koji sadrži antigen virusa influence ili antigenski preparat iz soja H5, H2, H9, H7 ili H6 virusa influence, u kombinaciji s adjuvansom, gdje količina antigena ne prelazi 4 µg haemaglutinina po dozi, gdje je navedeni adjuvans emulzija ulja u vodi, koja sadrži skvalen, tokoferol i emulgator, te gdje je antigen ili antigenski preparat u obliku podijeljenog virusa influence, i
– drugi imunogeni pripravak je monovalentni pripravak, koji sadrži virus influence H5, H2, H9, H7 ili H6, ili njegov antigenski preparat, koji je driftna varijanta virusa influence upotrijebljena u prvom cijepljenju, i
– ponovno cijepljenje se provodi 6-14 mjeseci nakon prvog cijepljenja.
2. Drugi imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što drugi imunogeni pripravak sadrži adjuvans.
3. Drugi imunogeni pripravak u skladu s patentnim zahtjevom 2, naznačen time što je navedeni adjuvans emulzija ulja u vodi kao adjuvans.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83143706P | 2006-07-17 | 2006-07-17 | |
GB0618195A GB0618195D0 (en) | 2006-09-15 | 2006-09-15 | Influenza vaccine |
GB0619090A GB0619090D0 (en) | 2006-09-27 | 2006-09-27 | Influenza vaccine |
PCT/EP2006/010439 WO2008009309A1 (en) | 2006-07-17 | 2006-10-27 | Influenza vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140488T1 true HRP20140488T1 (hr) | 2014-07-04 |
Family
ID=37909516
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140488TT HRP20140488T1 (hr) | 2006-07-17 | 2014-05-29 | Cjepivo protiv influence |
HRP20141122TT HRP20141122T1 (hr) | 2006-07-17 | 2014-11-19 | Cjepivo protiv influence |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20141122TT HRP20141122T1 (hr) | 2006-07-17 | 2014-11-19 | Cjepivo protiv influence |
Country Status (14)
Country | Link |
---|---|
US (4) | US9278127B2 (hr) |
EP (1) | EP2043682B1 (hr) |
JP (1) | JP5639760B2 (hr) |
KR (1) | KR101696727B1 (hr) |
CO (1) | CO6150191A2 (hr) |
CR (1) | CR10559A (hr) |
EA (1) | EA200900024A1 (hr) |
HR (2) | HRP20140488T1 (hr) |
IL (1) | IL196024A0 (hr) |
MA (1) | MA30624B1 (hr) |
MX (1) | MX2009000660A (hr) |
NO (1) | NO20090062L (hr) |
PL (1) | PL2043682T3 (hr) |
WO (1) | WO2008009309A1 (hr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
CA2601022C (en) * | 2005-03-23 | 2023-03-07 | Glaxosmithkline Biologicals S.A. | Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
EA017441B1 (ru) | 2006-06-15 | 2012-12-28 | Новартис Аг | Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы |
WO2008009309A1 (en) | 2006-07-17 | 2008-01-24 | Glaxosmithkline Biologicals S.A. | Influenza vaccine |
AR066405A1 (es) * | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | Vacuna |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
CA2716399C (en) | 2008-03-05 | 2020-07-21 | Pierre Chouvenc | Process for stabilizing an adjuvant containing vaccine composition |
EP2889042A3 (en) | 2008-03-18 | 2015-10-14 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
EP2310045A1 (en) | 2008-06-25 | 2011-04-20 | Novartis AG | Rapid responses to delayed booster immunisations |
CN102438651A (zh) | 2009-02-10 | 2012-05-02 | 诺华有限公司 | 用于大流行相关毒株的流感疫苗方案 |
AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
BR112012022939A2 (pt) * | 2010-03-11 | 2016-08-02 | Immune Design Corp | composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza |
US20120107354A1 (en) * | 2010-10-30 | 2012-05-03 | George Dacai Liu | Viral vaccine and process for preparing the same |
EP2578974A1 (en) | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Process line for the production of freeze-dried particles |
GB201205189D0 (en) | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
US20160228825A1 (en) | 2013-10-07 | 2016-08-11 | Novartis Ag | Treated filter |
CN107073350B (zh) | 2014-07-21 | 2019-11-15 | 赛诺菲巴斯德股份公司 | 用于产生液滴的液体给送装置 |
KR101729387B1 (ko) | 2015-04-17 | 2017-04-21 | 경희대학교 산학협력단 | 곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 m1-m2-na-ha 바이러스 유사 입자의 제조방법 |
US11305005B2 (en) * | 2015-06-24 | 2022-04-19 | Sanofi Pasteur Inc. | Methods of use of influenza vaccine for prevention of pneumonia |
GB201710414D0 (en) | 2017-06-29 | 2017-08-16 | Univ Nottingham | Chemotherapy |
US11369675B2 (en) * | 2018-01-22 | 2022-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
US11435351B2 (en) * | 2018-04-18 | 2022-09-06 | Biomadison, Inc. | Methods for determining vaccine potency |
KR102103638B1 (ko) * | 2018-06-01 | 2020-04-22 | 연세대학교 산학협력단 | 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
US5376369A (en) | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
DE69015222T2 (de) | 1989-02-04 | 1995-05-04 | Akzo Nv | Tocole als Impfstoffadjuvans. |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5969109A (en) | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
US5149531A (en) | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
DE4220757A1 (de) | 1992-06-24 | 1994-01-05 | Schering Ag | Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
WO1994019013A1 (en) | 1993-02-19 | 1994-09-01 | Smithkline Beecham Corporation | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
CN1124013A (zh) | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP0746338B1 (en) | 1994-02-24 | 2004-10-27 | Micro-Pak, Inc. | Vaccines containing paucilamellar lipid vesicles as immunological adjuvants |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
CA2330610A1 (en) | 1998-05-07 | 1999-11-11 | Corixa Corporation | Adjuvant composition and methods for its use |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
CA2689696C (en) | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20030158134A1 (en) | 2000-01-31 | 2003-08-21 | Gerald Voss | Vaccine for the prophylactic or therapeutic immunization against hiv |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
EP1201250A1 (en) | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogenic compositions comprising liver stage malarial antigens |
JP5208347B2 (ja) | 2001-02-23 | 2013-06-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規なワクチン |
MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
WO2003084467A2 (en) | 2002-04-01 | 2003-10-16 | Euro-Celtique S.A. | Epitope constructs comprising antigen presenting cell targeting mechanisms |
JP4675317B2 (ja) | 2003-01-30 | 2011-04-20 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | アジュバント化インフルエンザワクチン |
CA2559371C (en) * | 2004-03-09 | 2014-07-08 | Chiron Corporation | Influenza virus vaccines |
US7330082B2 (en) | 2004-08-23 | 2008-02-12 | Texas Instruments Incorporated | Oscillator system, method of providing a resonating signal and a communications system employing the same |
US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
CA2601022C (en) | 2005-03-23 | 2023-03-07 | Glaxosmithkline Biologicals S.A. | Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
AU2006310163B2 (en) * | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
NZ568210A (en) * | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
EP2377551A3 (en) * | 2005-11-04 | 2013-04-24 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
PT2368572T (pt) * | 2005-11-04 | 2020-06-16 | Seqirus Uk Ltd | Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
WO2008009309A1 (en) * | 2006-07-17 | 2008-01-24 | Glaxosmithkline Biologicals S.A. | Influenza vaccine |
CN105727276A (zh) | 2006-07-17 | 2016-07-06 | 葛兰素史密丝克莱恩生物有限公司 | 流感疫苗 |
BRPI0717219B8 (pt) | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
AR066405A1 (es) | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | Vacuna |
CA2707247A1 (en) * | 2007-12-06 | 2009-06-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
-
2006
- 2006-10-27 WO PCT/EP2006/010439 patent/WO2008009309A1/en active Application Filing
- 2006-10-27 JP JP2009519798A patent/JP5639760B2/ja active Active
- 2006-10-27 EA EA200900024A patent/EA200900024A1/ru unknown
- 2006-10-27 PL PL06806620T patent/PL2043682T3/pl unknown
- 2006-10-27 MX MX2009000660A patent/MX2009000660A/es active IP Right Grant
- 2006-10-27 KR KR1020097003223A patent/KR101696727B1/ko active IP Right Grant
- 2006-10-27 EP EP06806620.8A patent/EP2043682B1/en active Active
-
2008
- 2008-12-18 IL IL196024A patent/IL196024A0/en unknown
-
2009
- 2009-01-06 NO NO20090062A patent/NO20090062L/no not_active Application Discontinuation
- 2009-01-14 CR CR10559A patent/CR10559A/es not_active Application Discontinuation
- 2009-01-15 CO CO09003056A patent/CO6150191A2/es unknown
- 2009-02-04 MA MA31612A patent/MA30624B1/fr unknown
-
2011
- 2011-06-17 US US13/163,002 patent/US9278127B2/en active Active
-
2014
- 2014-05-29 HR HRP20140488TT patent/HRP20140488T1/hr unknown
- 2014-11-19 HR HRP20141122TT patent/HRP20141122T1/hr unknown
-
2016
- 2016-01-15 US US14/996,446 patent/US9943588B2/en active Active
-
2018
- 2018-03-14 US US15/920,519 patent/US10555999B2/en active Active
-
2019
- 2019-12-20 US US16/722,437 patent/US11564984B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009543816A (ja) | 2009-12-10 |
US20110243987A1 (en) | 2011-10-06 |
KR101696727B1 (ko) | 2017-01-16 |
US10555999B2 (en) | 2020-02-11 |
KR20090029851A (ko) | 2009-03-23 |
EP2043682B1 (en) | 2014-04-02 |
US20200360507A1 (en) | 2020-11-19 |
US20190054162A1 (en) | 2019-02-21 |
US11564984B2 (en) | 2023-01-31 |
IL196024A0 (en) | 2011-08-01 |
US20160256537A1 (en) | 2016-09-08 |
CO6150191A2 (es) | 2010-04-20 |
NO20090062L (no) | 2009-02-16 |
CR10559A (es) | 2009-03-20 |
JP5639760B2 (ja) | 2014-12-10 |
HRP20141122T1 (hr) | 2015-01-02 |
MA30624B1 (fr) | 2009-08-03 |
WO2008009309A1 (en) | 2008-01-24 |
US9278127B2 (en) | 2016-03-08 |
EP2043682A1 (en) | 2009-04-08 |
MX2009000660A (es) | 2009-04-08 |
EA200900024A1 (ru) | 2009-06-30 |
PL2043682T3 (pl) | 2014-09-30 |
US9943588B2 (en) | 2018-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140488T1 (hr) | Cjepivo protiv influence | |
EA200701786A1 (ru) | Поливалентная противогриппозная иммуногенная композиция | |
Bungener et al. | Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection | |
NZ594482A (en) | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant | |
NZ568210A (en) | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines | |
WO2017096341A3 (en) | Adenovirus-vectored multivalent vaccine | |
EA200901161A1 (ru) | Вакцина против гриппа в виде эмульсии типа "масло в воде" | |
Ghendon et al. | Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines | |
RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
JP2011504486A5 (hr) | ||
Atmar et al. | Adjuvants for pandemic influenza vaccines | |
JP2014532620A5 (hr) | ||
JP2008534467A5 (hr) | ||
PT2164510E (pt) | Composições de vacina em emulsão que compreendem antigénio e adjuvante na fase aquosa | |
EP2377551A3 (en) | Adjuvanted influenza vaccines including cytokine-inducing agents | |
WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
CO6300963A2 (es) | Una vacuna contra la malaria que comprende p. falciparum y p. vivax | |
RU2014140168A (ru) | Улучшенная вакцинация против гриппа | |
BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
EA201070014A1 (ru) | Внутрикожная вакцина против гриппа | |
Girard et al. | Report of the third meeting on “influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007 | |
MX2021010194A (es) | Vacunas contra la influenza multivalentes adyuvantadas. | |
SG160386A1 (en) | Novel composition | |
AR111910A2 (es) | Composición inmunogénica que comprende una formulación de adyuvante, composición de vacuna, procedimiento, usos, métodos | |
Fisher et al. | Adjuvanted vaccines against influenza in the elderly |